Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Ipilimumab with Chemoradiation in Inoperable Esophageal Cancer
NCT03437200Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in esophageal cancer comparing Chemoradiation + Nivolumab with Chemoradiation + Nivolumab + Ipilimumab (2 arms). Primary endpoint: 12-Month Progression-free survival. Started Jan 2019; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03437200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437200.